In this double-blind randomized phase III trial , patients with 1.5 10 ( 9 ) neutrophils/L were randomly assigned to subcutaneous injections of balugrastim 40 mg ( n = 153 ) or pegfilgrastim 6 mg ( n = 151 ) .